Literature DB >> 29900062

Systemic depletion of lymphocytes following focal radiation to the brain in a murine model.

Anna F Piotrowski1, Thomas R Nirschl2, Esteban Velarde2, Lee Blosser2, Sudipto Ganguly2, Kathleen H Burns2, Leo Luznik2, John Wong2, Charles G Drake3, Stuart A Grossman2.   

Abstract

Severe radiation-related lymphopenia is common and associated with decreased survival in patients with several solid tumors. As the mechanisms underlying systemic lymphopenia are poorly understood, we developed an animal model to study the effects of brain radiation on lymphocytes and cytokines. C57 BL/6 and BALB/c mice received focal brain irradiation (4 Gy x 10 fractions or 2 Gy x 30 fractions). Weekly total lymphocyte counts (TLC), lymphocyte subsets and cytokines in blood and lymph nodes were measured. Non-irradiated lymph nodes were collected and examined before, during, and after radiation. We found that systemic TLC decreased rapidly irrespective of mouse strain or radiation schedule. 4 Gy x 10 resulted in a 42% and 75% & 70% and 49% TLC reduction in C57 BL/6 and BALB/c mice respectively. 2 Gy x 30 caused a 70% / 49% decrease in TLC in C57 BL/6 and BALB/c. Similar trends were seen for total T cells, CD4+, regulatory T and CD8+ cells. Changes in lymph node architecture and cellular composition correlated with the development of systemic lymphopenia. Three weeks after radiation, TLC returned to 60-80% of baseline, preceded by increased IL-7 levels in the lymph nodes. Focal brain radiation in mice results in significant systemic lymphodepletion.

Entities:  

Keywords:  IL-7 cytokine; brain radiation; immunosuppression; lymphocytes; lymphodepletion; radiation-related lymphopenia

Year:  2018        PMID: 29900062      PMCID: PMC5993500          DOI: 10.1080/2162402X.2018.1445951

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  17 in total

1.  BETA RADIATION OF CIRCULATING BLOOD BY AN IMPLANTED SHIELDED Y90 SOURCE, PRELIMINARY REPORT OF TECHNIQUE.

Authors:  W H OLDENDORF; J T BURROUGHS; B CASSEN; L W WETTERAU
Journal:  J Nucl Med       Date:  1964-11       Impact factor: 10.057

2.  Studies on lymphocytes. I. Lymphopenia produced by prolonged extracorporeal irradiation of circulating blood.

Authors:  E P CRONKITE; C R JANSEN; G C MATHER; N O NIELSEN; E A USENIK; E R ADAMIK; C R SIPE
Journal:  Blood       Date:  1962-08       Impact factor: 22.113

3.  Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide.

Authors:  Stuart A Grossman; Xiaobu Ye; Glenn Lesser; Andrew Sloan; Hetty Carraway; Serena Desideri; Steven Piantadosi
Journal:  Clin Cancer Res       Date:  2011-07-07       Impact factor: 12.531

Review 4.  Harnessing the biology of IL-7 for therapeutic application.

Authors:  Crystal L Mackall; Terry J Fry; Ronald E Gress
Journal:  Nat Rev Immunol       Date:  2011-05       Impact factor: 53.106

5.  Primary brain tumors treated with steroids and radiotherapy: low CD4 counts and risk of infection.

Authors:  Michael A Hughes; Michele Parisi; Stuart Grossman; Lawrence Kleinberg
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-08-01       Impact factor: 7.038

6.  Lymphopenia association with gross tumor volume and lung V5 and its effects on non-small cell lung cancer patient outcomes.

Authors:  Chad Tang; Zhongxing Liao; Daniel Gomez; Lawrence Levy; Yan Zhuang; Rediet A Gebremichael; David S Hong; Ritsuko Komaki; James W Welsh
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-07-08       Impact factor: 7.038

7.  The etiology of treatment-related lymphopenia in patients with malignant gliomas: modeling radiation dose to circulating lymphocytes explains clinical observations and suggests methods of modifying the impact of radiation on immune cells.

Authors:  Susannah Yovino; Lawrence Kleinberg; Stuart A Grossman; Manisha Narayanan; Eric Ford
Journal:  Cancer Invest       Date:  2013-02       Impact factor: 2.176

8.  Survival in Patients With Severe Lymphopenia Following Treatment With Radiation and Chemotherapy for Newly Diagnosed Solid Tumors.

Authors:  Stuart A Grossman; Susannah Ellsworth; Jian Campian; Aaron T Wild; Joseph M Herman; Dan Laheru; Malcolm Brock; Ani Balmanoukian; Xiaobu Ye
Journal:  J Natl Compr Canc Netw       Date:  2015-10       Impact factor: 11.908

9.  Structural and functional features of central nervous system lymphatic vessels.

Authors:  Antoine Louveau; Igor Smirnov; Timothy J Keyes; Jacob D Eccles; Sherin J Rouhani; J David Peske; Noel C Derecki; David Castle; James W Mandell; Kevin S Lee; Tajie H Harris; Jonathan Kipnis
Journal:  Nature       Date:  2015-06-01       Impact factor: 49.962

10.  The Association Between Chemoradiation-related Lymphopenia and Clinical Outcomes in Patients With Locally Advanced Pancreatic Adenocarcinoma.

Authors:  Aaron T Wild; Xiaobu Ye; Susannah G Ellsworth; Jessica A Smith; Amol K Narang; Tanu Garg; Jian Campian; Daniel A Laheru; Lei Zheng; Christopher L Wolfgang; Phuoc T Tran; Stuart A Grossman; Joseph M Herman
Journal:  Am J Clin Oncol       Date:  2015-06       Impact factor: 2.339

View more
  4 in total

Review 1.  Immune Checkpoint Inhibitors for the Treatment of Central Nervous System (CNS) Metastatic Disease.

Authors:  Suneel D Kamath; Priya U Kumthekar
Journal:  Front Oncol       Date:  2018-09-27       Impact factor: 6.244

2.  Dosimetry of the brain and hypothalamus predicting acute lymphopenia and the survival of glioma patients with postoperative radiotherapy.

Authors:  Lu-Lu Ye; Xing-Wen Fan; Chao-Su Hu; Xia-Yun He; Xiao-Shen Wang; Chun-Ying Shen; Ting-Ting Xu; Hong-Mei Ying
Journal:  Cancer Med       Date:  2019-04-14       Impact factor: 4.452

Review 3.  How Non-invasive in vivo Cell Tracking Supports the Development and Translation of Cancer Immunotherapies.

Authors:  Madeleine Iafrate; Gilbert O Fruhwirth
Journal:  Front Physiol       Date:  2020-04-03       Impact factor: 4.566

Review 4.  Impact of General Factors on Glioma Immunotherapy.

Authors:  Qilin Huang; Dongmei Wang; Guojie Yao; Hongxiang Wang
Journal:  J Clin Neurol       Date:  2022-01       Impact factor: 3.077

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.